MDxHealth (MDXH) Stock Price, News & Analysis

Company Overview

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx. ConfirmMDx is an epigenetic assay performed on prostate biopsy tissue to identify men at risk of harboring occult high-grade prostate cancer following a negative biopsy result. SelectMDx is a non-invasive urine test designed to assess the likelihood of clinically significant prostate cancer before an initial biopsy, helping to reduce unnecessary procedures. Both tests are performed in MDxHealth’s CLIA-certified laboratory in the United States and its ISO-certified laboratory in Europe, and are used by urologists worldwide to guide biopsy and treatment decisions.

Founded in 2003, MDxHealth has established a global footprint, serving patients and healthcare providers across North America, Europe and select international markets through direct lab services and strategic partnerships. The company is led by President and CEO Caroline Palm, who brings extensive experience in molecular diagnostics and life sciences. MDxHealth is publicly traded on the Nasdaq under the ticker symbol MDXH.

Key Stats

• Today's Range: $3.62 to $3.82
• 50-Day Range: $2.18 to $3.83
• 52-Week Range: $1.35 to $3.91
• Volume: 18,386 shs
• Average Volume: 94,630 shs
• Market Capitalization: $176.91 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Buy

MDxHealth Stock Analysis - MarketRank™

MDxHealth scored higher than 42% of companies evaluated by MarketBeat, and ranked 550th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

MDxHealth has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

MDxHealth has a consensus price target of $7.00, representing about 90.2% upside from its current price of $3.68.

Amount of Analyst Coverage

MDxHealth has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for MDxHealth are expected to grow in the coming year, from ($1.15) to ($0.61) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MDxHealth is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MDxHealth is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

MDxHealth has a P/B Ratio of 11.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.16% of the float of MDxHealth has been sold short.

Short Interest Ratio / Days to Cover

MDxHealth has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MDxHealth has recently decreased by 1.43%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MDxHealth does not currently pay a dividend.

Dividend Growth

MDxHealth does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.16% of the float of MDxHealth has been sold short.

Short Interest Ratio / Days to Cover

MDxHealth has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MDxHealth has recently decreased by 1.43%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for MDxHealth this week, compared to 1 article on an average week.

Search Interest

4 people have searched for MDXH on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

2 people have added MDxHealth to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MDxHealth insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.70% of the stock of MDxHealth is held by insiders.

MDXH Stock Analysis - Frequently Asked Questions

How have MDXH shares performed this year?

MDxHealth's stock was trading at $2.37 at the beginning of 2025. Since then, MDXH stock has increased by 55.3% and is now trading at $3.68.

How were MDxHealth's earnings last quarter?

MDxHealth SA (NASDAQ:MDXH) released its earnings results on Tuesday, August, 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.02. The firm had revenue of $26.60 million for the quarter, compared to analysts' expectations of $26.60 million. MDxHealth had a negative net margin of 34.98% and a negative trailing twelve-month return on equity of 374.98%.
Read the conference call transcript.

When did MDxHealth's stock split?

MDxHealth's stock reverse split on Friday, December 29th 2023.The 1-10 reverse split was announced on Monday, October 2nd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did MDxHealth IPO?

MDxHealth (MDXH) raised $45 million in an initial public offering (IPO) on Thursday, November 4th 2021. The company issued 3,750,000 shares at a price of $12.00 per share.

Who are MDxHealth's major shareholders?

Top institutional investors of MDxHealth include Samjo Management LLC (3.25%), Delta Investment Management LLC (0.37%) and FreeGulliver LLC (0.26%).
View institutional ownership trends.

How do I buy shares of MDxHealth?

Shares of MDXH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of MDxHealth own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MDxHealth investors own include Cognition Therapeutics (CGTX), LAVA Therapeutics (LVTX), Coeptis Therapeutics (COEP), PHX Minerals (PHX), PayPal (PYPL), Arcadia Biosciences (RKDA) and Alimera Sciences (ALIM).

Company Calendar

• Last Earnings: 8/05/2025
• Today: 9/17/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: N/A
• Current Symbol: NASDAQ:MDXH
• CIK: 1872529
• Web: mdxhealth.com
• Phone: 324-364-2070
• Fax: 32042597875
• Employees: 300
• Year Founded: N/A

Price Target and Rating

• Average Price Target for MDxHealth: $7.00
• High Price Target: $8.00
• Low Price Target: $6.00
• Potential Upside/Downside: +90.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.88)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$38.07 million
• Net Margins: -34.98%
• Pretax Margin: -40.47%
• Return on Equity: -374.98%
• Return on Assets: -21.97%

Debt

• Debt-to-Equity Ratio: 13.81
• Current Ratio: 1.31
• Quick Ratio: 1.22

Sales & Book Value

• Annual Sales: $90.05 million
• Price / Sales: 1.93
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.31 per share
• Price / Book: 11.87

Miscellaneous

• Outstanding Shares: 47,290,000
• Free Float: 46,484,000
• Market Cap: $174.03 million
• Optionable: Not Optionable
• Beta: 1.49